TokenPost·
ImmunityBio Revenue Climbs 53% as Quarterly Loss Widens
Nine-month net product revenue rose 92% to $143.6 million. ImmunityBio plans to submit a supplemental biologics license application for BCG-naive patients before year-end.
More news
- TokenPostMichael Wilson Says Oil Fell Sharply Amid Hopes for Iran Progress
- TokenPostForrester Model Shows AI Capacity Outpacing Demand Absorption
- Crypto BriefingHouse to vote on impeachment resolution against Defense Secretary Hegseth today
- Crypto BriefingAnthropic workforce expands from 940 to 5,300 in under two years
- TokenPostZodl Begins OHTTP Rollout to Shield Zcash Wallet Users’ IP Addresses
- TokenPostElliptic Says North Korea-Linked Hackers Moved 117,000 NEAR